Neurology · AntidepressantRegulatory Approvalregulatorynear-term

Breckenridge's Milnacipran Hydrochloride ANDA205071 Receives AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 12:34:32 AM

Assessment confidence: 73% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Breckenridge's Milnacipran Hydrochloride under ANDA205071 is significant as it positions the company to compete more effectively in the antidepressant market. This development may prompt competitors to reassess their strategies in response to Breckenridge's enhanced market presence. Regulatory context from FDA (FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (15 high-relevance).

Strategic Assessment

Strategic focus on market entry and pricing strategies will be essential for Breckenridge to capitalize on this approval. The strongest clinical anchor is Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antidepressant, 8 regulatory and 7 competitive items passed relevance filtering for Breckenridge.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval may enhance Breckenridge's position in the antidepressant market, potentially impacting competitors with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL) (FDA). Entity match (breckenridge); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but ongoing monitoring of market entry and competitive responses will be crucial for maintaining regulatory alignment.

Key Risks

Elevated medium regulatory exposure for Breckenridge could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion) could weigh on Breckenridge through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms) could weigh on Breckenridge through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Breckenridge's entry with a new product could capture market share from existing antidepressants, influencing pricing and sales dynamics within the sector.
Strategic focus on market entry and pricing strategies will be essential for Breckenridge to capitalize on this approval.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch date and market response to Breckenridge's Milnacipran Hydrochloride product.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (breckenridge); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (breckenridge); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVOMILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Effect of Feeding Status on Appetite and Eating Behaviour.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Body Awareness Therapy in High Stressed Young Adults: Effects on Function, Balance, Sleep and Mood
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartishigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for AJOVY (Fremanezumab)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting lymphotoxin β receptor: from mechanism to precision therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Breckenridge
Milnacipran Hydrochloride

Commercial impact

medium

Breckenridge's entry with a new product could capture market share from existing antidepressants, influencing pricing and sales dynamics within the sector.

Regulatory impact

medium

The approval status indicates compliance with FDA standards, but ongoing monitoring of market entry and competitive responses will be crucial for maintaining regulatory alignment.

What to watch

Monitor for the launch date and market response to Breckenridge's Milnacipran Hydrochloride product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.